Phase 1 Trial of Eloralintide Injection to Assess Insulin Sensitivity and Metabolic Health in Adults with Overweight or Obesity

What this Trial Is About

Researchers are studying the effects of eloralintide compared to a placebo on insulin sensitivity, metabolic health, and body weight in adults who are overweight or have obesity. This phase 1 study focuses on understanding how these treatments influence how the body responds to insulin and other metabolic factors. Participants in this study are adults aged 18 to 70 years with a body mass index between 25 and 45 kgm, and without diabetes. Participants will be randomly assigned to receive either eloralintide or a placebo, both administered by subcutaneous injection. The study lasts about 35 weeks and includes 3 inpatient visits totaling 7 days. The design is double-blind, so neither the participants nor the researchers know who receives the active drug or placebo during the trial. During the study, participants will undergo assessments to measure changes in insulin sensitivity using a hyperinsulinemic euglycemic clamp test at baseline and week 24. Body weight changes will also be tracked over the same period. Participants must maintain lifestyle and dietary guidelines throughout the study. The research team will monitor safety and overall health during the visits and follow the participants until study completion around 2027.

A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity